Truist Financial Lowers Medline (NASDAQ:MDLN) Price Target to $47.00

Key Points

• Truist Financial lowered Medline’s price target from $56 to $47 while maintaining a “Buy” rating, implying 33.51% upside from the stock’s prior close. Analysts overall remain moderately bullish, with a consensus price target of $48.50.
• Medline reported quarterly EPS of $0.50, well above the $0.32 consensus, on $7.68 billion in revenue. However, the company lowered its full-year adjusted EBITDA outlook to $3.3–$3.4 billion due to inflation, higher costs, retail weakness and disruption from a distribution-center fire.
• Shares fell to $35.20, near the lower end of their 52-week range, while insider activity was mixed: one insider bought 5,000 shares and another sold 100,000 shares.

Medline (NASDAQ:MDLN - Get Free Report) had its price target decreased by Truist Financial from $56.00 to $47.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Truist Financial's price objective points to a potential upside of 33.51% from the company's previous close.

A number of other research firms have also recently commented on MDLN. Tigress Financial boosted their price objective on Medline from $60.00 to $62.00 and gave the company a "buy" rating in a research report on Wednesday, May 13th. Sanford C. Bernstein dropped their price target on shares of Medline from $56.00 to $54.00 and set an "outperform" rating on the stock in a research note on Thursday, May 7th. BNP Paribas Exane reduced their price objective on shares of Medline from $49.00 to $40.00 and set a "neutral" rating for the company in a research report on Thursday, May 14th. Citigroup decreased their price objective on shares of Medline from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Thursday, May 7th. Finally, Deutsche Bank Aktiengesellschaft set a $37.00 target price on shares of Medline in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Medline has a consensus rating of "Moderate Buy" and an average price target of $48.50.

Medline Stock Performance

Shares of NASDAQ MDLN traded down $1.47 during midday trading on Thursday, reaching $35.20. The company had a trading volume of 3,124,626 shares, compared to its average volume of 7,296,391. The business's 50-day simple moving average is $38.29 and its 200 day simple moving average is $41.83. Medline has a 1 year low of $32.81 and a 1 year high of $50.88. The company has a current ratio of 4.41, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. The stock has a market cap of $46.25 billion and a P/E ratio of 110.02.

Medline (NASDAQ:MDLN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.32 by $0.18. The business had revenue of $7.68 billion for the quarter. On average, analysts forecast that Medline will post 1.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jessi L. Corcoran acquired 5,000 shares of the firm's stock in a transaction on Friday, June 5th. The shares were bought at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the acquisition, the insider owned 5,000 shares of the company's stock, valued at approximately $170,750. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Douglas P. Golwas sold 100,000 shares of the company's stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the sale, the insider directly owned 23,899 shares of the company's stock, valued at $878,766.23. The trade was a 80.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.81% of the company's stock.

Institutional Investors Weigh In On Medline

Several hedge funds and other institutional investors have recently made changes to their positions in MDLN. Sound Income Strategies LLC purchased a new position in Medline during the fourth quarter worth about $25,000. Entrust Financial LLC acquired a new stake in Medline during the fourth quarter worth $26,000. GAMMA Investing LLC raised its position in Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company's stock valued at $25,000 after purchasing an additional 254 shares during the period. NBC Securities Inc. purchased a new position in shares of Medline during the 4th quarter worth $28,000. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Medline during the first quarter valued at about $30,000.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter adjusted EPS of $0.50, above the $0.32 analyst consensus, while sales rose 11.6% year over year to $7.7 billion. Adjusted EBITDA increased 13.4% to $1.06 billion, and management raised full-year organic sales growth guidance to 9%-10%. Medline Reports Second Quarter and First Six Months 2026 Results
• Positive Sentiment: BTIG analyst David Larsen reiterated a Buy rating and maintained a $55 price target, citing robust growth and viewing current headwinds as transitory. BTIG Medline Rating
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but lowered its price target from $50 to $45, reflecting more cautious expectations while still implying substantial potential upside from recent levels. Benzinga analyst report
• Negative Sentiment: Medline reduced its full-year adjusted EBITDA outlook to $3.3-$3.4 billion from $3.5-$3.6 billion. Management cited inflation, higher investment and remediation costs, retail-channel softness, and the operating impact of the Tracy, California distribution-center fire. The fire contributed to $336 million in losses, helping drive a 58.3% decline in quarterly net income to $139 million. Medline updates 2026 outlook
• Negative Sentiment: A law firm announced an investigation into possible securities-law violations involving Medline. The announcement is preliminary and does not establish wrongdoing, but it adds headline and litigation risk. Kaplan Fox investigation announcement

Medline Company Profile

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source